Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
5,674
Views
46
CrossRef citations to date
0
Altmetric
Back Matter

GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells

Christian M. Seitza Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0520-7866View further author information
ORCID Icon,
Sarah Schroedera Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GermanyView further author information
,
Philipp Knopfb Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, GermanyView further author information
,
Ann-Christin Krahla Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GermanyView further author information
,
Jana Haua Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GermanyView further author information
,
Sabine Schleichera Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GermanyView further author information
,
Manuela Martellac Department of Pathology, Eberhard Karls University Tuebingen, Tuebingen, GermanyView further author information
,
Leticia Quintanilla-Martinezc Department of Pathology, Eberhard Karls University Tuebingen, Tuebingen, GermanyView further author information
,
Manfred Kneillingb Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, GermanyView further author information
,
Bernd Pichlerb Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany;d Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyView further author information
,
Peter Langa Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GermanyView further author information
,
Daniel Atara Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GermanyView further author information
,
Karin Schilbacha Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GermanyView further author information
,
Rupert Handgretingera Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany;d Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyView further author information
&
Patrick Schlegela Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany;d Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyView further author information
 show all
Article: 1683345 | Received 10 Aug 2019, Accepted 16 Oct 2019, Published online: 07 Nov 2019

Citations (46)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Wen-Jing Ning, Xue Liu, Hong-Ye Zeng, Zhi-Qiang an, Wen-Xin Luo & Ning-Shao Xia. (2022) Recent progress in antibody-based therapeutics for triple-negative breast cancer. Expert Opinion on Drug Delivery 19:7, pages 815-832.
Read now
Chiara Corti, Konstantinos Venetis, Elham Sajjadi, Lorenzo Zattoni, Giuseppe Curigliano & Nicola Fusco. (2022) CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opinion on Investigational Drugs 31:6, pages 593-605.
Read now
Xuemei Xie, Jangsoon Lee, Toshiaki Iwase, Megumi Kai & Naoto T Ueno. (2022) Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opinion on Therapeutic Targets 26:5, pages 405-425.
Read now

Articles from other publishers (43)

Aurore Dougé, Nathan El Ghazzi, Richard Lemal & Paul Rouzaire. (2024) Adoptive T Cell Therapy in Solid Tumors: State-of-the Art, Current Challenges, and Upcoming Improvements. Molecular Cancer Therapeutics 23:3, pages 272-284.
Crossref
Tanuma Mistry, Arijit Nath, Ranita Pal, Sushmita Ghosh, Sutapa Mahata, Pranab Kumar Sahoo, Sinjini Sarkar, Trisha Choudhury, Partha Nath, Neyaz Alam & Vilas D. Nasare. (2024) Emerging Futuristic Targeted Therapeutics. American Journal of Clinical Oncology 47:3, pages 132-148.
Crossref
Krishna Mahanti & Sankar Bhattacharyya. (2024) Rough neighborhood: Intricacies of cancer stem cells and infiltrating immune cell interaction in tumor microenvironment and potential in therapeutic targeting.. Translational Research 265, pages 51-70.
Crossref
Diego F. Chamorro, Lauren K. Somes & Valentina Hoyos. (2023) Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential. Cancers 16:1, pages 124.
Crossref
Yan Yang, Guangming Zhu, Li Yang & Yun Yang. (2023) Targeting CD24 as a novel immunotherapy for solid cancers. Cell Communication and Signaling 21:1.
Crossref
Mohd Kausar, Sadaf Anwar, Hemat El‑Horany, Farida Khan, Neetu Tyagi, Mohammad Najm, - Sadaf, Alaa Eisa, Chandrajeet Dhara & Saumyatika Gantayat. (2023) Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review). International Journal of Oncology 63:6.
Crossref
Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu & Xi Gu. (2023) Advances in immunotherapy for triple-negative breast cancer. Molecular Cancer 22:1.
Crossref
Cristina Novaconi, Robert Onulov, Alina Serb, Eugen Sisu, Nicolae Dinca, Mihai-Cosmin Pascariu & Marius Georgescu. (2023) Assessing Glycosphingolipid Profiles in Human Health and Disease Using Non-Imaging MALDI Mass Spectrometry. Applied Sciences 13:17, pages 9922.
Crossref
Samaneh Keshavarz, Jack R. Wall, Somayeh Keshavarz, Elham Vojoudi & Reza Jafari-Shakib. (2023) Breast cancer immunotherapy: a comprehensive review. Clinical and Experimental Medicine 23:8, pages 4431-4447.
Crossref
Zhibo Zheng, Siyuan Li, Mohan Liu, Chuyan Chen, Lu Zhang & Daobin Zhou. (2023) Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy. Cancers 15:13, pages 3476.
Crossref
Xuefeng Jin & Guang-Yu Yang. (2023) Pathophysiological roles and applications of glycosphingolipids in the diagnosis and treatment of cancer diseases. Progress in Lipid Research 91, pages 101241.
Crossref
Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, Kirat K. Ganguly, Malini Basu & Mrinal K. Ghosh. (2023) Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes & Diseases 10:4, pages 1318-1350.
Crossref
Anuvab Dey, Subhrojyoti Ghosh, Shreya Jha, Subhranil Hazra, Nainika Srivastava, Urmimala Chakraborty & Anupriya Guha Roy. (2023) Recent advancement in breast cancer treatment using CAR T cell therapy:- A review. Advances in Cancer Biology - Metastasis 7, pages 100090.
Crossref
Peizhen Geng, Yuhua Chi, Yuan Yuan, Maoquan Yang, Xiaohua Zhao, Zhengchun Liu, Guangwei Liu, Yihui Liu, Liang Zhu & Shuai Wang. (2023) Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer. Frontiers in Cell and Developmental Biology 11.
Crossref
Qingjie He, Haibo Hu, Fan Yang, Dong Song, Xiaoling Zhang & Xiangpeng Dai. (2023) Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer. Biomedicine & Pharmacotherapy 162, pages 114609.
Crossref
Nicole Cruz-Reyes & Derek C. Radisky. (2023) Inflammation, Infiltration, and Evasion—Tumor Promotion in the Aging Breast. Cancers 15:6, pages 1836.
Crossref
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, Sara Bleve, Chiara Casadei, Cristian Lolli, Laura Ridolfi, Giovanni Martinelli & Ugo De Giorgi. (2023) The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. Cancers 15:5, pages 1597.
Crossref
Fatemeh Nasiri, Mehrasa Kazemi, Seyed Mohamad Javad Mirarefin, Maral Mahboubi Kancha, Milad Ahmadi Najafabadi, Faeze Salem, Setareh Dashti Shokoohi, Sahar Evazi Bakhshi, Pouya Safarzadeh Kozani & Pooria Safarzadeh Kozani. (2022) CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Frontiers in Immunology 13.
Crossref
Chunrun Qu, Hao Zhang, Hui Cao, Lanhua Tang, Haoyang Mo, Fangkun Liu, Liyang Zhang, Zhenjie Yi, Lifu Long, Luzhe Yan, Zeyu Wang, Nan Zhang, Peng Luo, Jian Zhang, Zaoqu Liu, Weijie Ye, Zhixiong Liu & Quan Cheng. (2022) Tumor buster - where will the CAR-T cell therapy ‘missile’ go?. Molecular Cancer 21:1.
Crossref
Yun Li, Huajun Zhang, Yulia Merkher, Lin Chen, Na Liu, Sergey Leonov & Yongheng Chen. (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. Journal of Hematology & Oncology 15:1.
Crossref
Hao Zhang, Shuangli Zhu, Wanjun Deng, Rui Li, Haiting Zhou & Huihua Xiong. (2022) The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. Frontiers in Immunology 13.
Crossref
Rui Zhang, Juchuanli Tu & Suling Liu. (2022) Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity. Seminars in Cancer Biology 82, pages 11-25.
Crossref
Alaa Alnefaie, Sarah Albogami, Yousif Asiri, Tanveer Ahmad, Saqer S. Alotaibi, Mohammad M. Al-Sanea & Hisham Althobaiti. (2022) Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Chenyi Luo, Peipei Wang, Siqi He, Jingjing Zhu, Yuanyuan Shi & Jianxun Wang. (2022) Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Frontiers in Oncology 12.
Crossref
Roberto Ruiu, Antonino Di Lorenzo, Federica Cavallo & Laura Conti. (2022) Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?. Frontiers in Oncology 12.
Crossref
Wolfgang Glienke, Anna Christina Dragon, Katharina Zimmermann, Alexandra Martyniszyn-Eiben, Mira Mertens, Hinrich Abken, Claudia Rossig, Bianca Altvater, Krasimira Aleksandrova, Lubomir Arseniev, Christina Kloth, Andriana Stamopoulou, Thomas Moritz, Holger N. Lode, Nikolai Siebert, Rainer Blasczyk, Lilia Goudeva, Axel Schambach, Ulrike Köhl, Britta Eiz-Vesper & Ruth Esser. (2022) GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Frontiers in Immunology 13.
Crossref
Angelina Kasprowicz, Groux-Degroote Sophie, Chann Lagadec & Philippe Delannoy. (2022) Role of GD3 Synthase ST8Sia I in Cancers. Cancers 14:5, pages 1299.
Crossref
Claire Shao, Vivek Anand, Michael Andreeff & Venkata Lokesh Battula. (2021) Ganglioside GD2: a novel therapeutic target in triple‐negative breast cancer. Annals of the New York Academy of Sciences 1508:1, pages 35-53.
Crossref
Elaine Zhong, Edi Brogi, Timothy M. D’Alfonso, Hannah Wen, Denise Frosina, Nai-Kong Cheung, Achim A. Jungbluth & Dara S. Ross. (2022) Expression Analysis of GD2 by Immunohistochemistry in Invasive Breast Carcinoma: Clinical and Pathologic Correlation. Applied Immunohistochemistry & Molecular Morphology 30:2, pages 113-118.
Crossref
Ganesan Ramamoorthi, Krithika Kodumudi, Corey Gallen, Nadia Nocera Zachariah, Amrita Basu, Gabriella Albert, Amber Beyer, Colin Snyder, Doris Wiener, Ricardo L.B. Costa & Brian J. Czerniecki. (2022) Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Seminars in Cancer Biology 78, pages 78-89.
Crossref
Farhana Yesmin, Robiul H. Bhuiyan, Yuhsuke Ohmi, Satoko Yamamoto, Kei Kaneko, Yuki Ohkawa, Pu Zhang, Kazunori Hamamura, Nai-Kong V. Cheung, Norihiro Kotani, Koichi Honke, Tetsuya Okajima, Mariko Kambe, Orie Tajima, Keiko Furukawa & Koichi Furukawa. (2021) Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins. International Journal of Molecular Sciences 23:1, pages 423.
Crossref
Ali Bashiri Dezfouli, Mina Yazdi, Alan Graham Pockley, Mohammad Khosravi, Sebastian Kobold, Ernst Wagner & Gabriele Multhoff. (2021) NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. Cells 10:12, pages 3390.
Crossref
Kuba Retecki, Milena Seweryn, Agnieszka Graczyk-Jarzynka & Malgorzata Bajor. (2021) The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers 13:23, pages 6012.
Crossref
Cenzhu Wang, Kun Xu, Runtian Wang, Xin Han, Jinhai Tang & Xiaoxiang Guan. (2021) Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Ramona Erber, Sareetha Kailayangiri, Hanna Huebner, Matthias Ruebner, Arndt Hartmann, Lothar Häberle, Julia Meyer, Simon Völkl, Andreas Mackensen, Laura Landgraf, Carol I. Geppert, Rüdiger Schulz-Wendtland, Matthias W. Beckmann, Peter A. Fasching, Nicole Farwick, Claudia Rossig & Paul Gass. (2021) Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers 13:21, pages 5577.
Crossref
Estelle Baulu, Aurore Dougé, Nicolas Chuvin, Jacques-Olivier Bay & Stéphane Depil. (2021) Approches d’immunothérapie cellulaire T dans les tumeurs solides. Bulletin du Cancer 108:10, pages S96-S108.
Crossref
Eric Gyan, William K.B.A. Owiredu, Linda Ahenkorah Fondjo, Andrew M. Jackson, Andrew R. Green & Ganiyu A. Rahman. (2021) A review of the racial heterogeneity of breast cancer stem cells. Gene 796-797, pages 145805.
Crossref
Chiara Donini, Ramona Rotolo, Alessia Proment, Massimo Aglietta, Dario Sangiolo & Valeria Leuci. (2021) Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. Cells 10:3, pages 543.
Crossref
Stanley Ly, Vivek Anand, Fouad El-Dana, Khoa Nguyen, Yiming Cai, Shirong Cai, Helen Piwnica-Worms, Debasish Tripathy, Aysegul A Sahin, Michael Andreeff & Venkata Lokesh Battula. (2021) Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2 + breast cancer stem-like cells . Journal for ImmunoTherapy of Cancer 9:3, pages e001197.
Crossref
Cesar Gentille Sanchez, Thomas Pfeiffer & Bilal A. Omer. 2021. Uveal Melanoma. Uveal Melanoma 213 225 .
Sundee Dees, Rajkumar Ganesan, Sanjaya Singh & Iqbal S. Grewal. (2020) Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 19:12, pages 2409-2421.
Crossref
Margarita Bartish, Sonia V. del Rincón, Christopher E. Rudd & H. Uri Saragovi. (2020) Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy. Frontiers in Immunology 11.
Crossref
Bassel Nazha, Cengiz Inal & Taofeek K. Owonikoko. (2020) Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Frontiers in Oncology 10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.